At equimolar concentrations NVP-BEZ235 exerted relatively more potent antitumor effect compared with mTOR inhibitors (temsirolimus, everolimus) against bladder and breast cancer cells (Fig. 3). The gene discussed is MTOR; the disease is breast cancer.